Article
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
European journal of cancer (Oxford, England : 1990) - 1 Dec 2020
Peng Xingzhou, Long Xiaoyan, Liu Li, Zeng Liang, Yang Haiyan, Jiang Wenjuan, Liao Dehua, Li Kunyan, Wang Jing, Lizaso Analyn, Mao Xinru, Xu Qinqin, Mansfield Aaron S, Yang Nong, Zhang Yongchang
Abstract excerpt
AIM: Our study aimed to evaluate the efficacy and resistance mechanisms of first-line epidermal growth factor receptor (EGFR) inhibitor therapy in patients with advanced non-small-cell lung cancer (NSCLC) harbouring uncommon EGFR exon 19 deletion-insertion (19delins) variants. METHODS: Targeted sequencing data of 2467 treatment-naive patients with NSCLC from January 2015 to August 2018 were retrospectively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.